SCHEMBL19682407

SCHEMBL19682407

COC(=O)c1cc(Cl)cc(Cl)c1S(=O)(=O)Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.42
SERPINH1 P50454 1/20 0.42
FLT1 P17948 1/20 0.41
FLT4 P35916 1/20 0.41
KDR P35968 1/20 0.41
GAA P10253 3/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
ALDH1A1 P00352 3/20 0.40
TSHR P16473 1/20 0.40
PDK2 Q15119 1/20 0.38
NR4A2 P43354 2/20 0.38
ACLY P53396 1/20 0.38
MAPT P10636 2/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
NQO2 P16083 1/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30821925 0.84 ABL1 (0.41) ABL1SERPINH1SLC6A4SLC6A3ALDH1A1
SCHEMBL19682390 0.84 ABL1 (0.41) ABL1SERPINH1SLC6A4SLC6A3ALDH1A1
SCHEMBL30298258 0.84 GAA (0.45) ABL1SERPINH1FLT1FLT4KDR
SCHEMBL24457828 0.77 ACLY (0.44) ABL1SERPINH1GAASLC6A4SLC6A3
SCHEMBL7033458 0.77 NR4A2 (0.48) SLC6A4SLC6A3ALDH1A1TSHRNR4A2
SCHEMBL4468249 0.75 ACLY (0.51) ABL1SERPINH1SLC6A4SLC6A3PDK2
SCHEMBL423691 0.75 AKR1C4 (0.60) ABL1SERPINH1GAASLC6A4SLC6A3
SCHEMBL14341400 0.75 ABL1 (0.47) ABL1SERPINH1GAASLC6A4SLC6A3
SCHEMBL21999818 0.74 ACLY (0.53) ABL1SERPINH1GAASLC6A4SLC6A3
SCHEMBL13159074 0.74 ABL1 (0.46) ABL1SERPINH1GAASLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2025-05-01 US disclosed
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity GLUCOX BIOTECH AB (SE) 2025-01-21 US disclosed
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2021-06-10 US disclosed
EP-3790858-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY Glucox Biotech AB (SE) 2021-03-17 EP disclosed
CN-112384497-A Novel sulfonamide derivatives having selective NOX inhibitory activity 格卢科克斯生物科技有限公司 2021-02-19 CN disclosed
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 US disclosed
EP-3718545-A1 ANTITUMOR AGENT Taiho Pharmaceutical Co., Ltd. (JP) 2020-10-07 EP disclosed
US-20200157066-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-05-21 US disclosed
WO-2019215291-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY GLUCOX BIOTECH AB (SE) 2019-11-14 WO disclosed
EP-3466934-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2019-04-10 EP disclosed
WO-2017209155-A1 SULFONAMIDE COMPOUND OR SALT THEREOF 大鵬薬品工業株式会社 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399235-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 ABL1 2441/4885SERPINH1 391/4885FLT1 2340/4885
US-12202790-B2 Sulfonamide derivatives having selective Nox inhibiting activity NOX4, NOX1, NOX5 ABL1 381/4885SERPINH1 1443/4885FLT1 3521/4885
US-20210171456-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY NOX4, NOX1, NOX5 ABL1 408/4885SERPINH1 1221/4885FLT1 3402/4885
US-20250136545-A1 NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY NOX4, NOX1, NOX5 ABL1 408/4885SERPINH1 1221/4885FLT1 3402/4885
US-20200157066-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 ABL1 2441/4885SERPINH1 391/4885FLT1 2340/4885
US-10889555-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 ABL1 2441/4885SERPINH1 391/4885FLT1 2340/4885
US-20200405697-A1 Antitumor Agent HNRNPR, RRM2, RRM2B ABL1 2821/4885SERPINH1 679/4885FLT1 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.